Accurexa to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

NEWARK, DE / ACCESSWIRE / September 1, 2015 / Accurexa Inc. (the “Company”) (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies that can deliver therapeutics directly into the brain, announced today that it will present at the 17th Annual Rodman & Renshaw Global Investment Conference taking place from September 8-10, 2015 at the St. Regis Hotel in New York City.

George Yu, MD, President & CEO, is scheduled to present on Wednesday, September 9 at 10:00 AM ET and will be available to participate in one-on-one meetings. If you are an institutional investor and would like to schedule a one-on-one meeting with the management team, please contact David Burke of The Ruth Group at 646-536-7009, or dburke@theruthgroup.com.

Event: 17th Annual Rodman & Renshaw Global Investment Conference
Date: Wednesday, September 9, 2015
Time: 10:00 AM (Eastern Time)
The presentation will be available for download at http://www.accurexa.com/investors.html.

About Accurexa, Inc.

The Company is focused on developing novel neurological therapies that can deliver therapeutics directly into specific regions of the brain. It is developing its ACX-31 program which could deliver chemotherapy drugs, such as temozolomide in combination with BCNU, directly to brain tumor sites. Temozolomide is a generic, approved, first-line chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012. However, current standard of care of delivering temozolomide to tumor sites through oral administration is limited by the blood-brain-barrier and orally administered temozolomide increases patient survival by 2.5 months from a 12.1 months median overall survival.

Animal studies at the Johns Hopkins School of Medicine* have shown that local delivery of temozolomide increased concentrations of the drug in the brain threefold and increased survival up to fourfold compared with oral administration. The percentage of long-term survivors for groups receiving local delivery of temozolomide ranged from 25% to 37.5% while there were no long-term survivors with orally administered temozolomide. Further animal studies at the Johns Hopkins School of Medicine** have shown that the additive effect of combined delivery of local temozolomide with local BCNU, especially in combination with radiotherapy, was significantly more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. Groups treated with combination of local temozolomide, local BCNU and radiation therapy had 75% long-term survivors.

The Company’s BranchPoint device was invented to deliver multiple therapeutics, such as stem cells, chemotherapy or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration. The current standard of care is the use of straight, rigid needles, often requiring surgeons to penetrate the brain multiple times for delivering therapeutics, which in turn may increase the risk of bleeding, stroke and reflux of therapeutics back out to the brain surface. An animal study at UCSF# (University of California, San Francisco) demonstrated that the use of a straight needle was associated with reflux of at least 75% of the infusion while no reflux was found with the BranchPoint device.

Additional information about the Company may be found on its website, www.accurexa.com.

Notes:

* Brem S, Tyler BM, Li K, Pradilla G, Legnani F, Caplan J, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007; 60:643-50.

** Renard Recinos V, Tyler BM, Brem H, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 2010; 66:530-537.

# Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to successfully develop and commercialize novel neurological therapies based on its BranchPoint device or U.S. Patent No. 8,895,597 B2, or its ACX-31 program and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Contact Investor Relations:

David Burke
The Ruth Group
Tel.: 646-536-7009
dburke@theruthgroup.com

Accurexa Inc.
info@accurexa.com
Tel.: 302-709-1822

SOURCE: Accurexa Inc.

ReleaseID: 431650